Abstract
Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.
Keywords:
ARNi; Angiotensin receptor–neprilysin inhibitor; Heart failure; LCZ696.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
MeSH terms
-
Aminobutyrates / pharmacology
-
Aminobutyrates / therapeutic use*
-
Angiotensin II Type 1 Receptor Blockers / pharmacology
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Angiotensin Receptor Antagonists / pharmacology
-
Angiotensin Receptor Antagonists / therapeutic use*
-
Biphenyl Compounds
-
Clinical Trials as Topic / methods
-
Drug Combinations
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Humans
-
Neprilysin / antagonists & inhibitors*
-
Neprilysin / metabolism
-
Renin-Angiotensin System / drug effects*
-
Renin-Angiotensin System / physiology
-
Tetrazoles / pharmacology
-
Tetrazoles / therapeutic use*
-
Valsartan
Substances
-
Aminobutyrates
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin Receptor Antagonists
-
Biphenyl Compounds
-
Drug Combinations
-
Tetrazoles
-
Valsartan
-
Neprilysin
-
sacubitril and valsartan sodium hydrate drug combination